GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel

Core Viewpoint - Gilead Sciences, Inc. (GILD) is set to acquire Arcellx (ACLX) for $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion, enhancing Gilead's position in cell therapy [1][8] Acquisition Details - The acquisition focuses on anito-cel, a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma, which has demonstrated deep and durable responses with a manageable safety profile [4][11] - Gilead's subsidiary Kite Pharma already collaborates with Arcellx to co-develop anito-cel, indicating a strategic alignment between the two companies [2][11] - The deal includes a tender offer for all remaining Arcellx shares at a 68% premium to the 30-day volume-weighted average share price as of February 20, 2026 [9] Financial Implications - The acquisition is expected to be accretive to Gilead's earnings from 2028, strengthening its oncology and cell therapy portfolio [10][11] - Gilead currently holds approximately 11.5% of Arcellx's outstanding shares, which will be fully acquired through this transaction [9] Strategic Rationale - The acquisition allows Gilead to gain full control of anito-cel, streamlining development and commercialization processes, thereby enhancing long-term margin potential [11] - Gilead aims to diversify its revenue base and ramp up its oncology franchise, which has been under pressure [12] Market Context - Gilead anticipates ongoing competitive pressure in the cell therapies market, particularly from new entrants and established players like Bristol Myers (BMY), which has a strong cell-therapy portfolio [13] - The addition of anito-cel is expected to help Gilead offset declines in its existing cell therapy business [13]